GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (STU:94E) » Definitions » Capex-to-Operating-Income

Zura Bio (STU:94E) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Zura Bio's Capital Expenditure for the three months ended in Mar. 2025 was €-0.05 Mil. Its Operating Income for the three months ended in Mar. 2025 was €-17.81 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Zura Bio Capex-to-Operating-Income Historical Data

The historical data trend for Zura Bio's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Capex-to-Operating-Income Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24
Capex-to-Operating-Income
- - -

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zura Bio's Capex-to-Operating-Income

For the Biotechnology subindustry, Zura Bio's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Zura Bio's Capex-to-Operating-Income falls into.


;
;

Zura Bio Capex-to-Operating-Income Calculation

Zura Bio's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-4.847) / -52.705
=N/A

Zura Bio's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.045) / -17.81
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zura Bio  (STU:94E) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Zura Bio Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Zura Bio's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio Business Description

Industry
Traded in Other Exchanges
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Headlines

No Headlines